Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor

NCT06922344 | Recruiting Phase 4

• 1 other identifier: 84/DME/KMC
• Study Type: interventional
• Target: 106
• Locations: 1 country
• Sites: 1

Brief Summary

This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.

Conditions

Pityriasis Versicolor

Keywords

Pityriasis Versicolor; Fluconazole; Itraconazole

Outcome Measures

Primary Outcomes (1)

• Efficacy of Treatment

  Efficacy of treatment is defined by absence of scaling by naked eye examination ,absence of yellow or golden scale reflection on woods lamp examination and absence of fungal hyphae on microscopic examination.

  Upto 8 weeks

Study Arms (2)

Group A, Fluconazole group

EXPERIMENTAL

Group A consists of patients in whom oral fluconazole is given in dose of 300mg once weekly for 2 weeks.

Drug: Fluconazole

Group B, Itraconazole group

EXPERIMENTAL

Group B consists of patients in whom oral Itraconazole is given in dose of 100mg Twice for 5 days.

Drug: Itraconazole

Interventions

Fluconazole DRUG

Oral fluconazole prescribed to group A

Group A, Fluconazole group

Itraconazole DRUG

Oral itraconazole prescribed to Group B

Group B, Itraconazole group

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• All cases of Pityriasis versicolor

You may not qualify if:

• Patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities.
• Patients who received any anti-fungal therapy in the last one month.
• Pregnant or lactating women.

Sponsors & Collaborators

• Khyber Teaching Hospital: lead

Study Sites (1)

Khyber Teaching Hospital

Peshawar, KPK, 25000, Pakistan

RECRUITING

MeSH Terms

Conditions

Tinea Versicolor

Interventions

Fluconazole; Itraconazole

Condition Hierarchy (Ancestors)

Dermatomycoses; Mycoses; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Piperazines

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: April 3, 2025
• First Posted: April 10, 2025
• Study Start: March 1, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: April 10, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)